Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 1
2016 4
2017 4
2018 6
2019 5
2020 8
2021 4
2022 8
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C, Sripadam R, Mukherjee S, Soonawalla Z, Wadsley J, Al-Mukhtar A, Dickson E, Graham J, Jiao L, Wasan HS, Tait IS, Prachalias A, Ross P, Valle JW, O'Reilly DA, Al-Sarireh B, Gwynne S, Ahmed I, Connolly K, Yim KL, Cunningham D, Armstrong T, Archer C, Roberts K, Ma YT, Springfeld C, Tjaden C, Hackert T, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer. Ghaneh P, et al. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):157-168. doi: 10.1016/S2468-1253(22)00348-X. Epub 2022 Dec 12. Lancet Gastroenterol Hepatol. 2023. PMID: 36521500 Free article. Clinical Trial.
United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer.
Oldfield L, Stott M, Hanson R, Jackson RJ, Reynolds W, Chandran-Gorner V, Van Der Meer R, Alison L, Tejeiro R, Purewal T, Ghaneh P, Palmer D, Greenhalf W, Halloran C, Costello E. Oldfield L, et al. BMJ Open. 2022 Oct 10;12(10):e068010. doi: 10.1136/bmjopen-2022-068010. BMJ Open. 2022. PMID: 36216424 Free PMC article.
A Multicenter, Randomized, Double-Blinded, Clinical Trial Comparing Cattell-Warren and Blumgart Anastomoses Following Partial Pancreatoduodenectomy: PANasta Trial.
Halloran CM, Neoptolemos JP, Jackson R, Platt K, Psarelli EE, Reddy S, Gomez D, O'Reilly DA, Smith A, Pausch TM, Prachalias A, Davidson B, Ghaneh P. Halloran CM, et al. Ann Surg Open. 2022 Sep 15;3(3):e198. doi: 10.1097/AS9.0000000000000198. eCollection 2022 Sep. Ann Surg Open. 2022. PMID: 36199490 Free PMC article.
Recent advances in understanding pancreatic cancer.
Stott MC, Oldfield L, Hale J, Costello E, Halloran CM. Stott MC, et al. Fac Rev. 2022 Apr 20;11:9. doi: 10.12703/r/11-9. eCollection 2022. Fac Rev. 2022. PMID: 35509672 Free PMC article. Review.
Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes.
Oldfield L, Evans A, Rao RG, Jenkinson C, Purewal T, Psarelli EE, Menon U, Timms JF, Pereira SP, Ghaneh P, Greenhalf W, Halloran C, Costello E. Oldfield L, et al. EBioMedicine. 2022 Jan;75:103802. doi: 10.1016/j.ebiom.2021.103802. Epub 2022 Jan 3. EBioMedicine. 2022. PMID: 34990893 Free PMC article.
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA.
Aughton K, Elander NO, Evans A, Jackson R, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, Carter R, Cunningham D, Tebbutt NC, Goldstein D, Shannon J, Glimelius B, Hackert T, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Palmer DH, Büchler MW, Ghaneh P, Neoptolemos JP, Greenhalf W. Aughton K, et al. Cancers (Basel). 2021 Nov 17;13(22):5758. doi: 10.3390/cancers13225758. Cancers (Basel). 2021. PMID: 34830914 Free PMC article.
40 results